The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4122-4127

  Chigutsa, Emmanuel ^a   Visser, Marianne E ^b   Swart, Elizabeth C ^b   Denti, Paolo ^a   Pushpakom, Sudeep ^c   Egan, Deirdre ^c   Holford, Nicholas H G ^d   Smith, Peter J ^a   Maartens, Gary ^a   Owen, Andrew ^c   McIlleron, Helen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; CONSTITUTIVE ANDROSTANE RECEPTOR; DNA; ETHAMBUTOL; ISONIAZID; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; PREGNANE X RECEPTOR; PYRAZINAMIDE; RIFAFOUR; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EXPOSURE; ETHNICITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMULATION; SOUTH AFRICA; STEADY STATE; TRANSCRIPTION REGULATION; WILD TYPE;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RIFAMPIN; SOUTH AFRICA; YOUNG ADULT;

EID: 80051803484     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01833-10     Document Type: Article

References (29)

1. Agrawal, S., et al. 2004. Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol. Res. 50:317-327. (Pubitemid 38844487)
2. Ahn, J E, M O Karlsson, A. Dunne, and T M Ludden. 2008. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35:401-421.
3. Anderson, B J, and N H Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
4. Barrett, J C, B. Fry, J. Maller, and M J Daly. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265. (Pubitemid 40202029)
5. Burman, W J, et al. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338. (Pubitemid 44156613)
6. Diacon, A H, et al. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996. (Pubitemid 47206244)
7. Dorman, S E, et al. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
8. Gurumurthy, P., et al. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48:4473-4475. (Pubitemid 39434921)
9. Health and Medical Publishing Group. 2010. South African medicines formulary, 9th ed. Health and Medical Publishing Group, Cape Town, South Africa.
10. Jayaram, R., et al. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124. (Pubitemid 36753560)
11. Kim, R B 2003. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest. 33(Suppl. 2):1-5.
12. Lamba, J., V. Lamba, S. Strom, R. Venkataramanan, and E. Schuetz. 2008. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos. 36:169-181.
13. Lubomirov, R., et al. 2010. ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet. Genomics 20:217-230.
14. McIlleron, H., et al. 2007. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J. Antimicrob. Chemother. 60:1398-1401.
15. McIlleron, H., et al. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
16. Mitnick, C D, B. McGee, and C A Peloquin. 2009. Tuberculosis pharmacotherapy: Strategies to optimize patient care. Expert Opin. Pharmacother. 10:381-401.
17. Moriya, Y., et al. 2002. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25:1356-1359. (Pubitemid 39663201)
18. Perlman, D C, et al. 2005. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41:1638-1647. (Pubitemid 41691604)
19. Sakaeda, T., et al. 2001. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:1400-1404. (Pubitemid 32977244)
20. Sanofi-Aventis. 2007. Rifadin (rifampin) product monograph, version 3.0:15. Sanofi-Aventis, Quebec, Canada.
21. Schuetz, E G, A H Schinkel, M V Relling, and J D Schuetz. 1996. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 93:4001-4005. (Pubitemid 26144235)
22. Siccardi, M., et al. 2008. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 47:1222-1225.
23. Tappero, J W, et al. 2005. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41:461-469. (Pubitemid 41099637)
24. Tirona, R G, B F Leake, A W Wolkoff, and R B Kim. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304:223-228. (Pubitemid 36008932)
25. Tishkoff, S A, and S M Williams. 2002. Genetic analysis of African populations: Human evolution and complex disease. Nat. Rev. Genet. 3:611-621. (Pubitemid 34827135)
26. Visser, M E, et al. 10 November 2010, posting date. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am. J. Clin. Nutr. [Epub ahead of print.] doi:10.3945/ajcn.110.001784.
27. Weiner, M., et al. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491. (Pubitemid 40628637)
28. Weiner, M., et al. 2010. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54:4192-4200.
29. Wilkins, J J, et al. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. (Pubitemid 351758551)